Cargando…
1995. Duration of letermovir primary prophylaxis in hematopoietic cell transplant recipients at high risk for cytomegalovirus infections and impact on outcomes
BACKGROUND: The incidence of clinically significant cytomegalovirus infection (CS-CMVi) in high risk allo-HCT recipients who are CMV seropositive (R+) has decreased in the era of letermovir (LTV) primary prophylaxis (PP) which is also associated with a reduction in all-cause mortality (ACM) and non-...
Autores principales: | Febres-Aldana, Anthony J, Khawaja, Fareed, Spallone, Amy, Srinivasan, Krithika, Lynn Shigle, Terri, Morado Aramburo, Oscar, Rondon, Gabriella, Ramdial, Jeremy, Shpall, Elizabeth, Ariza Heredia, Ella, Chemaly, Roy F, Sassine, Joseph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678504/ http://dx.doi.org/10.1093/ofid/ofad500.122 |
Ejemplares similares
-
2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022) -
2122. The Impact of HHV-6 DNAemia on hematopoietic cell transplant (HCT) recipients at high risk for CMV reactivation in the era of Letermovir
por: Srinivasan, Krithia, et al.
Publicado: (2022) -
922. The Impact of Clinically Significant CMV Infections on Other Viral Infections in the Era of Letermovir Primary Prophylaxis
por: Spallone, Amy, et al.
Publicado: (2021) -
580. Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era
por: Sassine, Joseph, et al.
Publicado: (2020) -
2119. Predictive Value of the Immunodeficiency Scoring Index for COVID-19 Related Outcomes in Hematopoietic Transplant Recipients
por: Daher, Marilyne, et al.
Publicado: (2022)